Effect of the potentiation of cholinergic activity on the variability in individual GH response to GH-releasing hormone
- PMID: 2515219
- DOI: 10.1007/BF03350063
Effect of the potentiation of cholinergic activity on the variability in individual GH response to GH-releasing hormone
Abstract
In man the GH response to GHRH is highly variable and some normal subjects may be completely unresponsive to the neuropeptide. On the other hand, the potentiation of cholinergic activity by pyridostigmine (PD), a cholinesterase inhibitor, increases the GH response to GHRH, probably by inhibiting somatostatin release. The aim of this study was to assess the existence of intraindividual variability in the GH response to GHRH and verify the effects of PD treatment on inter- and intraindividual variability. Twenty normal adults (17 M and 3 F) and 10 normal prepubertal children (9 M and 1 F) underwent 2-5 administrations of 1 micrograms/kg GHRH on different days. Seven adults and all children also underwent 1-5 other tests in which GHRH was preceded (60 min before) by oral PD (120 mg in adults and 60 mg in children). The GH responses to GHRH were highly variable, not only within subjects but also in the same subject on different occasions (peak range; adults: 0.4-49.0 ng/ml; children: 2.4-50.0 ng/ml). PD always markedly increased the GH response to GHRH, even unmasking this response in 3 adults and 4 children hyporesponsive to the neuropeptide alone. However, the variability in the GH response was still present (adults: 27.2-108.5 ng/ml; children: 25.0-144.0 ng/ml), though reduced (adults: p = 0.0005; children: p = 0.0204). These data indicate that: i. A great inter- and intraindividual variability in the GH response to GHRH is present.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Involvement of brain catecholamines and acetylcholine in growth hormone deficiency states. Pathophysiological, diagnostic and therapeutic implications.Drugs. 1991 Feb;41(2):161-77. doi: 10.2165/00003495-199141020-00002. Drugs. 1991. PMID: 1709847 Review.
-
Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.Clin Endocrinol (Oxf). 1997 Oct;47(4):495-500. doi: 10.1046/j.1365-2265.1997.3081114.x. Clin Endocrinol (Oxf). 1997. PMID: 9404449 Clinical Trial.
-
The role of cholinergic tone in modulating the growth hormone response to growth hormone-releasing hormone in normal man.Metabolism. 1991 May;40(5):519-23. doi: 10.1016/0026-0495(91)90234-n. Metabolism. 1991. PMID: 2023538 Clinical Trial.
-
Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycemia on growth hormone (GH) releasing hormone-induced GH secretion in man: does acute hyperglycemia act through hypothalamic release of somatostatin?Neuroendocrinology. 1989 May;49(5):551-4. doi: 10.1159/000125166. Neuroendocrinology. 1989. PMID: 2566942 Clinical Trial.
-
Neuroactive drugs in growth disorders.Acta Paediatr Scand Suppl. 1990;367:33-7. doi: 10.1111/j.1651-2227.1990.tb11629.x. Acta Paediatr Scand Suppl. 1990. PMID: 2220385 Review. No abstract available.
Cited by
-
Somatostatinergic tone in children on chronic haemodialysis and after renal transplantation.Pediatr Nephrol. 1991 Jul;5(4):548-51. doi: 10.1007/BF01453699. Pediatr Nephrol. 1991. PMID: 1680365
-
Involvement of brain catecholamines and acetylcholine in growth hormone deficiency states. Pathophysiological, diagnostic and therapeutic implications.Drugs. 1991 Feb;41(2):161-77. doi: 10.2165/00003495-199141020-00002. Drugs. 1991. PMID: 1709847 Review.
-
Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults.Endocrine. 2001 Jun;15(1):29-38. doi: 10.1385/ENDO:15:1:029. Endocrine. 2001. PMID: 11572322 Review.
-
Variability in the growth hormone response to growth hormone-releasing hormone alone or combined with pyridostigmine in type 1 diabetic patients.J Endocrinol Invest. 1993 Sep;16(8):585-90. doi: 10.1007/BF03347676. J Endocrinol Invest. 1993. PMID: 8258646 Clinical Trial.
-
Therapeutical doses of salbutamol inhibit the somatotropic responsiveness to growth hormone-releasing hormone in asthmatic children.J Endocrinol Invest. 1993 Apr;16(4):271-5. doi: 10.1007/BF03348828. J Endocrinol Invest. 1993. PMID: 8514982
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources